Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weight loss programme may ease heart symptoms in seniors with AF

NCT ID NCT03713775

Symptom relief Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a commercial meal replacement weight loss programme could reduce atrial fibrillation (AF) symptoms in overweight adults aged 60-85 with persistent AF. 119 participants were randomly assigned to either the weight loss programme or usual care for 32-36 weeks. The main goal was to see if symptoms improved, measured by a standard AF symptom questionnaire.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
meal replacement weight loss programme
What this could lead to
If successful, this weight loss programme could offer a simple, non-drug way to ease AF symptoms in older adults.
What could go wrong
This is a small, early-stage trial (119 participants) with no blinding. Results may not apply to all AF patients, and weight loss can be hard to maintain long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

119 people

The number who actually took part.

Started

Nov 2018

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Persistent AF * Body mass index ≥27 kg/m2 Exclusion Criteria: * Planned catheter ablation for AF within 8 months * Learning difficulties or unable to understand English * Participation in another research trial involving an investigational product or weight loss programme in the prior 3 months * Current treatment with anti-obesity drugs * Uncontrolled endocrine disorders * Diabetes requiring insulin * Active gout or history of recurrent gout * Ongoing gallbladder disease * Serious underlying medical or psychiatric disorder; e.g., known cancer or any other significant disease affecting short-term life expectancy; severe valvular disease, myocardial infarction or stroke within the previous 6 months; severe heart failure; eating disorder or purging behaviour; severe psychotic disorder requiring hospitalisation or supervised care, active liver disease (except non-alcoholic fatty liver disease). * Unintentional weight loss of more than 5 kg within the prior 6 months * Gastrointestinal malabsorption * Unstable INR (persistently \<2 for \>14 days) or supra-therapeutic levels with concomitant bleeding or requiring hospitalisation * Substance abuse * Taking varenicline (smoking cessation medication) * Chronic renal failure of stage 4 or 5 * Porphyria

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation Overweight and obesity

Contacts and locations

Locations

  • Oxford Centre for Magnetic Resonance (OCMR)

    Oxford, Oxfordshire, OX3 9DU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.